New hope for Platinum-Resistant ovarian cancer: BL-M07D1 enters phase 3 trial

NCT ID NCT07545460

Not yet recruiting Disease control Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 30, 2026 · Updated 3 times

Summary

This Phase 3 trial compares a new drug called BL-M07D1 against standard chemotherapy in 404 people with HER2-expressing ovarian, fallopian tube, or peritoneal cancer that has become resistant to platinum-based treatment. Participants will receive either BL-M07D1 or one of several chemotherapies chosen by their doctor. The study aims to see if BL-M07D1 can delay cancer growth or improve survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BL-M07D1 (a drug given by IV every 3 weeks)
What this could lead to: If it works, this could offer a new treatment option for people with hard-to-treat ovarian cancer that has stopped responding to platinum chemotherapy.
What could go wrong: This is an early-stage Phase 3 trial, so results are not yet known. The drug may not work better than existing chemotherapies, and side effects could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPITHELIAL OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Carcinoma, Ovarian Epithelial fallopian tube cancer fallopian tube neoplasm ovarian carcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EPITHELIAL OVARIAN CANCER FALLOPIAN TUBE CANCER PRIMARY PERITONEAL CANCER

Contacts and locations

Locations

Cancer Hospital Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, China
Yunnan Cancer Hospital

Kunming, Yunnan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.